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Abstract
Background: Although it has been estimated that pandemic Influenza A H1N1/2009 has infected millions of people from
April to October 2009, a more precise figure requires a worldwide large-scale diagnosis of the presence of Influenza A/
H1N1/2009 antibodies within the population. Assays typically used to estimate antibody titers (hemagglutination inhibition
and microneutralization) would require the use of the virus, which would seriously limit broad implementation.
Methodology/Principal Findings: An ELISA method to evaluate the presence and relative concentration of specific
Influenza A/H1N1/2009 antibodies in human serum samples is presented. The method is based on the use of a histidine-
tagged recombinant fragment of the globular region of the hemagglutinin (HA) of the Influenza A H1N1/2009 virus
expressed in E. coli.
Conclusions/Significance: The ELISA method consistently discerns between Inf A H1N1 infected and non-infected subjects,
particularly after the third week of infection/exposure. Since it does not require the use of viral particles, it can be easily and
quickly implemented in any basic laboratory. In addition, in a scenario of insufficient vaccine availability, the use of this
ELISA could be useful to determine if a person has some level of specific antibodies against the virus and presumably at
least partial protection.
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Introduction
Seasonal influenza causes thousands of deaths annually,
worldwide. In the United States alone, more than 50,000 patients
die yearly due to influenza-like illness and its consequences [1].
Influenza continues to be a disease that causes major suffering and
economic loss to modern societies [2–6].
On April 26
th 2009, an epidemiological emergency related to an
Influenza A H1N1virus was declared in Me ´xico [7,8]. During the
first few weeks of surveillance, the virus spread worldwide to 30
countries (as of May 11) by human-to-human transmission. By
June 2009, only a few weeks later, Influenza A/H1N1/2009 was
declared a Level VI Pandemic by the World Health Organization
(WHO) [8,9]. This represented the first time in history that a
disease had been designated at this risk level.
The total number of people infected around the world is difficult
to estimate, and the diagnosis efforts have been surpassed by the
advance of the disease. It is believed that, in the period between
April-December 2009, millions of people were infected. By the end
of the year 2009, WHO had declared that 12,000 persons had
died due to Influenza A/H1N1; half of them in North America
(Me ´xico, Canada and USA). On the other hand, a significant
fraction of the world population may already have been exposed to
the virus (between 12 [10] and 40% [11,12]) and, although
asymptomatic, could be at least partially immune to the disease
[10–12].
A more precise assessment of the total number of persons that
have been infected would require the large scale use of techniques
to specifically determine the presence and relative concentration of
2009 H1N1 influenza virus antibodies in serum samples. Besides
its obvious epidemiological significance, the availability of these
types of techniques would also allow the rapid discernment of
potentially immune subjects among those more susceptible to
infection in a given population. This is particularly relevant in a
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10176situation where there is insufficient availability of vaccine, such as
the one that was experienced in most developing countries,
including Me ´xico, the epicenter of this pandemic.
Typically, titration of anti-influenza antibodies is based on
experiments that evaluate the ability of a serum sample to inhibit
hemagglutination (Figure 1). Hemagglutinin is the most external
and most antigenic surface protein of influenza viruses. As its
name suggests, it induces hemagglutination by specifically binding
erythrocyte surface receptors (Figure 1a). At a fixed viral
concentration, and in the presence of an HA binding molecule
(e.g., neutralizing antibodies from a convalescent influenza
patient), the observed hemagglutination inhibition should be
proportional to the concentration of the inhibitor (Figure 1b). This
is the basic concept behind the hemagglutination inhibition (HI)
assay [13].
HI has become a relatively universal protocol for estimating
antibody titers against a particular influenza strain. The lowest
dilution of a viral suspension at which serum samples still inhibit
agglutination is determined by visual inspection and indicates
neutralization titer. Recent literature includes a number of
examples of the application of HI assays in the context of
epidemiological or clinical studies [10–12,14,15], in vaccine
development [16,17], in analytical development [18], or in more
fundamental studies. However, HI assays are not infallible for
some applications and they posses several important limitations.
Although HI titers have been strongly recommended [19] and
are commonly used to predict and qualify vaccine efficacy, the use
of titers often fails when live attenuated vaccines are evaluated,
because the assay does not encompass all of the immune mediators
of protection [18]. Strictly speaking, HI titers only indicate
interference of some anti-HA antibodies with the sialidated
receptors at the erythrocyte membrane. Consequently, adequate
performance of the titer test also depends on the nature and
quality of the erythrocytes used [20]. More importantly, for
practical implementation, HI assays require the use of viruses. In
the context of epidemiological studies, the analysis of hundreds to
thousands of samples is typical [10–12,14,21]. To conduct these
studies using standard HI assays demands an immense supply of
virus, which in turn requires the implementation of virus
propagation protocols and involvement of specially trained
personnel. In addition, particularly in the case of highly infective
or new influenza strains, level II or III bio-safety laboratory spaces
and protocols would also be mandatory for safe implementation of
virus culture.
Recently, a number of alternatives to HI have been investigated.
One of these is the microneutralization method, which has also
increased in use for evaluating the titer of neutralizing antibodies
[14,15,21,22]. However, microneutralization methods also rely on
the use of the actual virus. In addition, its standardization for a
particular influenza strain is not a trivial procedure [22]. Several
immunological-based methods have also been proposed to
qualitatively or quantitatively evaluate the presence of anti-
influenza antibodies in animal or human serum samples
[23,24,25,26].
In the present paper, we document the development and use of
an ELISA method that will specifically recognize 2009 H1N1
influenza virus antibodies in human serum samples, based on use
of a recombinant fragment of the globular region of the protein
hemagglutinin (HA) of the 2009 H1N1 virus. This protein,
produced in E. coli, specifically and effectively recognizes
antibodies from serum obtained from positive H1N1 virus-infected
patients, as diagnosed by standard PCR protocols [27], in samples
taken as soon as two weeks after infection. In addition, this antigen
can be massively produced and easily purified by standard
methodologies, providing the possibility of large scale supply
sufficient for large epidemiological studies.
The immunoassay proposed here shows significant advantages
over conventional HI assays; primarily: (a) it does not require fresh
chicken or turkey erythrocytes (which are limited in their
commercial availability); (b) it does not require virus manipulation
(and therefore does not require special infrastructure or safety
protocols); and (c) interpretation of results rests on absorbance
readings, instead of subjective visual estimations of agglutination.
Results and Discussion
Rationale of the assay
The structures of HA antigenic sites vary not only among
different subtypes of viruses but also within the same subtype. The
continuous antigenic drifts and occasional antigenic shifts that
arise from this continuous evolutionary variation enable human
influenza viruses to escape the human immune system [28].
Neutralizing antibodies are generally regarded as not broadly
cross-reactive among HA subtypes. Indeed, influenza A viruses
Figure 1. Hemagglutination inhibition assay. (A) Schematic
representation of hemagglutination using Influenza viral particles. In
the absence of agglutinationon inhibitors, the hemagglutinin from viral
capsids (1) agglutinates chicken, turkey or human erythrocytes(2). (B)
Schematic representation of hemagglutination inhibition. In the
presence of neutralizing antibodies (1) that specifically recognize the
hemagglutinin from a influenza virus (2), the process of hemaggluti-
nation is inhibited proportionally to the concentration and binding
affinity of the neutralizing antibodies.
doi:10.1371/journal.pone.0010176.g001
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determined by neutralization or hemagglutination inhibition (HI)
tests using polyclonal antisera to the respective HA subtypes,
which have little cross-reactivity to the other HA subtypes. To our
knowledge, there is only one report [29] of a monoclonal antibody,
directed to a well conserved conformational epitope in influenza A
viruses, that is capable of recognizing several different HA
serotypes (H1, H2, H3, H5, H9, H13).
Circulating H1N1/2009 influenza virus is antigenically distinct
from seasonal human A(H1N1) [30] and other seasonal influenza
A viruses [21]. Therefore, conceptually, an ELISA method could
be used to conclusively discriminate between subjects previously
exposed to 2009 H1N1 influenza virus and those not exposed. If
we accept that these immunogenic differences between the 2009
H1N1 influenza virus and other previously or actually circulating
strains exist, then a sufficiently specific immunological test should
also discriminate between subjects exposed to 2009 H1N1
influenza virus and other influenza A viruses. With this type of
assay, we also avoid the use of viral particles by using a
recombinant protein, the HA fragment of the 2009 H1N1
influenza virus (specific details will be provided later) produced
in E. coli as the antigen of an ELISA method. E. coli was chosen as
expression host due to the simplicity of producing large quantities
(of the order of 1 to 3 g/L) of recombinant proteins in a short time
period using standard bacterial culture techniques. We found that
this fragment of HA can be specifically recognized by antibodies
directed against the 2009 H1N1 influenza virus.
From a more fundamental perspective, one of the most
important contributions of this work is the conclusive demonstra-
tion that a recombinant antigen from bacterial origin (and
therefore not glycosylated) can be specifically recognized by
human antibodies targeted against a specific influenza strain.
Glycosylation is normally viewed as playing a role in antigen-
antibody recognition. However, for influenza virus, the mandatory
requirement of glycosylation for adequate antigenic biorecognition
has not been demonstrated [31–33].
Five antigenic sites, all located in the globular region of
hemagglutinin, have been conclusively identified in influenza A
H1N1viruses [29,34–39]. Some of them are in the vicinity but not
associated with glycosylation sites [39–41]. Indeed, all of them
have been reported to be individually accessible to specific
antibodies [29,34,36,38,39].
In addition, reports [42,43] from Song et al. and Chiu et al.
have demonstrated that fractions of HA expressed in E. coli, and
therefore non-glycosylated, are immunogenic in animal models.
These HA fragments corresponded to the globular region,
particularly to the HA1 domain.
We have successfully expressed a 25 kDa fragment of the
globular region of the hemagglutinin of the 2009 H1N1 influenza
virus (i.e. Influenza A/Mexico/InDRE4114/2009(H1N1))
(Figure 2) in the Rosseta-gami strain of E. coli [44,45]. This
protein, designated in our study as HA50–274-H1N1, ranges from
residues 50 to 274 of the amino acid sequence of the
hemagglutinin of the influenza 2009 H1N1 influenza virus. This
is a highly conserved region (above 99% preserved) among the
sequences of 2009 H1N1 influenza virus reported at NCBI. This
protein conserves all antigenic sites previously reported for HA
[29] and, as we demonstrate in the following section, specifically
and selectively recognizes antibodies from serum samples of
convalescent 2009 H1N1 influenza virus infected patients. We also
added a sequence coding for a series of six histidines at the N-
terminus of the protein (Figure 2) to facilitate downstream
processes (this strategy allowed purification using Immobilized
Metal Affinity Chromatography (IMAC)) and attachment to assay
surfaces treated with anti-histidine antibodies (or alternatively
Co
+2 or Ni
+2) (Figure 3a,3b).
HA50–274-H1N1 protein preferentially recognizes
antibodies from H1N1(+) patients
Serum from patients infected with 2009 H1N1 influenza virus
(as diagnosed using RT-PCR) specifically recognized the recom-
binant protein HA50–274-H1N1. Under certain conditions, this
specific recognition could be used to conclusively discern serum
samples from patients exposed and those from non-exposed
subjects. In preliminary experiments, different ELISA strategies
were tested in addition to the one detailed in the Materials and
Methods section (see Figure 3). For example, direct binding of
serum antibodies or protein HA50–274-H1N1 to the assay wells, as
a first step of the assay, was examined. Based on our experimental
observations, the method described here yields adequate repro-
ducibility and a high signal/noise ratio. For adequate perfor-
mance, dilution of serum samples was needed. In experiments
comparing the absorbance signal in undiluted serum samples from
infected and non-infected patients, a signal ratio (absorbance in
samples from infected subjects/absorbance in healthy volunteers)
of 1.39–1.59 was observed. When different dilutions (serum
samples in PBS) were tested, in the range of 1:50 to 1:200, the
signal ratio improved significantly (see Figure 4A).
For instance, typical signals in negative controls, using the
anti-histidine antibodies and the HA50–274-H1N1 protein (with
no serum addition), ranged between 0.050 and 0.070 absor-
bance units, with variance coefficients lower than 5%. Typical
signals from serum samples of non-infected volunteers ranged
between 0.15 and 0.40 absorbance units, with typical variance
coefficients of less than 5% and standard deviations lower than
0.01 units. Typical signals of 2009 H1N1 influenza virus
infected volunteers (as diagnosed by RT-PCR [27]) were at
least 1.5 times higher.
We propose that diagnosis of exposure to the 2009 H1N1
influenza virus with this ELISA can be predicted on absorbance
that is normalized to that of serum from uninfected subjects.
Consequently, for reliable results, the inclusion of samples of non-
exposed subjects (uninfected) subjects on every assay microplate is
necessary. Therefore, for relative comparison among samples,
absorbance values should be normalized based on the signal of one
or several non-exposed subjects (uninfected subjects), and
expressed as normalized absorbance (Absnorm), defined by
equation 1:
Absnorm~
Abssample { Abscontrol
 
Absnon exposed subjects{ Abscontrol
 ð1Þ
where, Abssample is the absorbance signal of the sample, Abscontrol
is the absorbance signal of a negative serum albumin control,
Absnon exposed subjects is the average absorbance signal of samples
from non-exposed subjects.
Protein HA50–274-H1N1can be consistently produced
Recent experimental evidence confirms that the main antigenic
sites in HA of the H1N1 influenza viruses are conformational
[29,37]. Therefore, proper folding of any recombinant influenza
antigen is essential for adequate recognition. As an illustration,
Chiu et al. documented the production of the HA1 domain of the
hemagglutinin of the H5N1 influenza virus in E. coli cultures, its
purification from inclusion bodies, and its proper solubilization,
refolding and purification by affinity chromatography [43]. In
their experiments, sera from convalescent animals challenged with
H1N1/2009 ELISA
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fragments from HA. Remarkably, the activity of the recovered
protein, exclusively measured in terms of specific recognition from
infected rat serum antibodies, was strongly dependant on the
refolding method [43].
Correct folding, into a form resembling the native structure of
the corresponding HA fragment of the 2009 H1N1 influenza virus,
should be considered as crucial for adequate biological recogni-
tion. A series of experiments were therefore conducted to establish
proper refolding of protein HA50–274 from inclusion bodies. For
this purpose, a native soluble form of the HA50–274 protein was
produced by expression in E. coli BL21 (DE3) pLysS variant C41,
using a genetic construct that included a peptide signal for
periplasmic expression. HA50–274 protein obtained by this method
was taken as a reference of proper folding. Selective biorecognition
of the native soluble and the refolded HA50–274-H1N1 protein by
antibodies in serum from 2009 H1N1 influenza virus positive
patients was established. Refolded HA50–274-H1N1 exhibited
more than 90% selective bio-recognition with respect to native
soluble HA50–274-H1N1 (Figure 4B) at different dilutions (1:50,
1:100 and 1:200). This was consistently observed among different
batches of the protein (A5a and 5B). Proper folding, defined here
as the ratio of absorbance readings of serum from infected subjects
obtained using originally soluble protein and refolded protein, was
typically around 1 (+/20.1) for all the production batches
analyzed (see Figure 5A). Selective bio-recognition, defined as
the ratio of absorbance signal between serum from a positive and a
negative subject, was similar for different assays conducted with
the same serum samples, regardless of the use of different protein
production batches (Figure 5B). A more detailed documentation of
the process of production and purification of protein HA50–274-
H1N1 can be found elsewhere [45].
Evolution of specific HA50–274-H1N1antibody titers after
infection
Significant antibody response to a new antigen in humans is
normally considered to occur within two to three weeks of
exposure. Some recent studies [15] have validated this for the
specific case of influenza infection. Our results suggest that
normalized absorbance values higher than two can be observed as
soon as six or seven days after the onset of disease (Figure 6A).
However, we consistently observed better discriminatory perfor-
mance of the assay when performed with samples taken from
patients three weeks after exposure to the 2009 H1N1 influenza
virus.
The proposed immunoassay was used to follow the evolution of
specific anti-influenza A/H1N1 titers in patients diagnosed as
H1N1 positive. According to our observations, in most 2009
Figure 2. Strategy used to express protein HA50–274-H1N1 in E. coli. The DNA region specifically encoding for the HA amino-acid sequence
between residues 50 and 274 was preceded by a promoter region and added in the N-terminus with a sequence encoding for a histydine tag.
doi:10.1371/journal.pone.0010176.g002
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PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10176Figure 3. ELISA method designed to evaluate the relative concentration of specific antibodies (Y) anti-influenza A/H1N1/2009 virus
in human serum and plasma. (A) Adsorption of anti-hystidine antibodies to the assay surface on 96-wells micro-assay plates and blockage of the
remaining available surface with a commercial blocking solution. (B) Addition of the recombinant protein HA50–274-H1N1 (semi-circles). (C) Addition of
serum samples potentially containing specific antibodies (Y) against the Influenza A H1N1/2009 virus. The left hand panel illustrates a scenario with a
higher concentration of specific influenza antibodies. (D) Addition of a peroxidated anti-IgG human antibody (Y) to specifically bind the retained
serum antibodies. (E) The addition of peroxidase substrate (S) enables the enzymatic reaction (SRP) with a proportional development of color.
doi:10.1371/journal.pone.0010176.g003
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PLoS ONE | www.plosone.org 5 April 2010 | Volume 5 | Issue 4 | e10176Figure 4. Serum from patients infected with Influenza A H1N1/2009 specifically recognize recombinant protein HA50–274-H1N1. (A)
Results corresponding to undiluted serum samples and three different dilutions of serum in phosphate buffer saline solution (PBS) are presented
(1:50, 1:100 and 1:200). Blue bars correspond to absorbance signal from samples of healthy subjects. Red bars correspond to absorbance signal from
samples of patients diagnosed as positive for Influenza A H1N1 taken three weeks after infection. Error bars were calculated based on the maximum
percentage of variance (100*Average signal/standard deviation). (B) The ratio of the absorbance signal exhibited by a sample from a positive patient/
absorbance signal of a sample from a healthy volunteer is presented. Results corresponding to three different serum dilutions (1:50, 1:100 and 1:200)
and two types of protein are presented (protein obtained directly in soluble form (columns identified as 1,2 and 3); and protein obtained after
dissolution and refolding from inclusion bodies (columns identified as 4,5 and 6). Three replicates of each observation were considered. Error bars
were calculated based on standard deviation.
doi:10.1371/journal.pone.0010176.g004
H1N1/2009 ELISA
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cases) specific antibody titers fluctuated around a basal value
during the first two week after infection. In these cases, two to
three weeks after the positive diagnosis, the absorbance signal at
least doubled its basal value. However, in 2 out of six cases,
infected subjects doubled their basal absorbance signal as soon as
six or seven days after onset of disease (Figure 6A). A similar
pattern was observed in experiments where ferrets were immu-
nized with protein HA50–274-H1N1 and monitored using the
ELISA protocol described here (data not shown).
These results suggest that specific anti-2009 H1N1 influenza
antibody titers could rise even during the first week after infection
and in most cases will at least double their basal value by the third
week after the onset of disease. Therefore, the immunoassay
documented here is best suited for the analysis of antibody titers in
samples from subjects exposed to the virus at least three weeks
previously. Based on samples from a limited number of
convalescent patients (5 cases), antibody titers appear to remain
high at least seven months after infection (see Figure 6B). In
general, a decrease in the normalized absorbance signal of less
than 1.5 units was observed among convalescent patients followed
from June 2009 to February 2010.
Discrimination between infected and non-infected
subjects
Figure 7 shows results for the determination of the relative
presence of 2009 H1N1 influenza virus antibodies in serum
samples of volunteers, using the ELISA protocol described here. In
all cases, 1:50 serum dilutions in PBS were used. Results from
three groups of volunteers are presented: (a) non exposed
volunteers (serum samples taken from March to May 2008), (b)
non infected subjects or 2009 H1N1 influenza-infected volunteers
(one week after being diagnosed); and (c) patients diagnosed as
Figure 5. Indirect evaluation of proper refolding. (A) Biorecognition of antibodies from a positive patient observed for different production
batches of protein HA50–274-H1N1. (B) Specific biorecognition ratio (ratio of biorecognition of antibodies from a positive patient serum and a negative
subject serum) observed at different refolding batches derived from the same E. coli culture experiment. Variation among batches consisted in minor
variations in the dissolution and refolding protocol used.
doi:10.1371/journal.pone.0010176.g005
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the most probable onset of disease).
Absorbance values were normalized based on the average signal
of non-exposed subjects, and expressed as normalized absorbance
(Absnorm), defined by equation 1.
Samples from non-exposed subjects and negative subjects
exhibited normalized absorbance values between 0.6 and 1.25.
Variability in samples from negative subjects (and non exposed
subjects) was relatively low, compared to absorbance values in
samples with high specific serum antibodies titers. In the
population tested, all serum samples corresponding to subjects
within the third and fourth weeks after positive diagnosis exhibited
absorbance values 2.0 to 4.5 times higher than samples from
negative volunteers (Figure 7). Therefore, when normalized
absorbance is used, the immunoassay appeared to clearly discern
between serum samples from non-exposed subjects and samples
from subjects exposed to the 2009 H1N1 influenza virus at least
three to four weeks before. Based on our observations, a
normalized absorbance value above 1.5 predicts exposure to the
virus. Assay sensibility was further validated against results from
Hemagglutination inhibition assays. Fifteen samples from subjects
that exhibited positive titers in HI assays performed using the A/
California/04/2009 virus were also analyzed by the described
ELISA. Results are presented in Figure 8. All these samples
Figure 6. Evolution of the normalized absorbance signal of serum samples from patients diagnosed as positive to Influenza A/
H1N1/2009. (A) Samples from two distinct patients were taken during the first three weeks after the onset of disease. Specific antibody titers more
than double their basal value after day 7. (B) Samples from a patient taken at day 21, 100, and 215 after the onset of disease reveal that antibody
titters remained high for at least seven months. Patients were diagnosed using RT-PCR protocols (WHO, 2009).
doi:10.1371/journal.pone.0010176.g006
H1N1/2009 ELISA
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general, high HI titters (.320) were correlated with normalized
absorbance values higher than 4.0.
Assay variability
The assay variability observed within the same ELISA
experimental set was relatively low with respect to the absorbance
signal, due to specific biorecognition. Error bars in Figure 6,7 and
8 indicate one standard deviation calculated from three repetitions
of the ELISA runs in different wells within the same micro-assay
plate. In order to characterize the assay variability among different
ELISA experiments, a group of six serum samples from different
volunteers and representative of different absorbance levels were
selected. For each of these samples, assays were conducted in three
different micro-assay plates with different reagent stocks. Each
assay was carried out in triplicate. Each bar in Figure 9 represents
the average of three experiment repetitions and at least nine assays
in total (including replicates within each micro-plate). Error bars
for samples 1,3,4,5, and 6 indicate the magnitude of one standard
deviation, based on each set of at least nine experimental
determinations. To establish the reproducibility and robustness
of the assay among the whole spectrum of possible anti-2009
H1N1 influenza titters, the results presented in Figure 8 were
selected to include cases with low, moderate, and high specific
antibody titers.
From the five cases of samples presented, only one case
exhibited important deviations (variability coefficients higher than
23%). In the rest of the cases, variability coefficients ranged
between 5 and 15%. This variability did not compromise the
ability of the method to discern between samples from exposed
and non-exposed subjects. Bar 2 represents the average normal-
ized absorbance and the standard deviation (error bars) associated
with the analysis of eight serum samples from non-exposed
subjects (samples taken from March to May 2008). The variability
Figure 7. Serum from patients infected with Influenza A H1N1/2009 specifically recognize protein HA50–274-H1N1. Bars 1–8 (gray)
correspond to absorbance signals from non-exposed subjects (samples taken from March to May 2008). Bar 9 (black) shows the average absorbance
value of samples 1 to 8. Bars 10 to 14 (blue colors) correspond to absorbance signals from Inf A/H1N1 negative subjects. Bars 15–26 (different colors)
correspond to absorbance signals from samples of Inf A H1N1 positive subjects (diagnosed two or three weeks before by RT-PCR). All signals were
normalized with respect to the average absorbance signal observed in samples from non-exposed volunteers. Error bars form samples 1–8 and 10–26
represent one standard deviation based on at least three replicates on the assay in the same micro-plate experiment. Error bars form sample 9
represent one standard deviation based on all assays performed to samples from non-exposed volunteers.
doi:10.1371/journal.pone.0010176.g007
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negative controls) was lower than 15%. Bar 1 corresponds to a
sample from a healthy volunteer, presumably not exposed, whose
normalized absorbance signal is statistically similar to that
observed for non-exposed volunteers. The variability coefficient
for this sample was determined as 20%. Bars 3 to 6 correspond to
serum from subjects diagnosed as positive to 2009 H1N1 influenza
virus between two and three weeks before the sample was taken.
Statistically, the specific antibody titer exhibited by each one of
these three samples is significantly higher than that determined for
non-exposed subjects.
Identification of exposed subjects within high risk
populations
A feasible relevant application of the method described here is
the identification of subjects who may be asymptomatic but who
have indeed been exposed to the 2009 H1N1 influenza virus and
therefore exhibit some level of specific antibodies. Presumably,
these subjects would display at least partial protection against
infection. Their identification would allow a more effective and
rational vaccine administration in scenarios of limited supply.
Serum samples from asymptomatic volunteers considered at
high exposure risk (health workers or staff from an Influenza
H1N1 diagnostic unit) were analyzed using the protocols described
here. Of the 28 samples tested, 22 corresponded to medical
personnel (medical doctors, nurses, and other health care workers)
in close contact with patients diagnosed as infected with 2009
H1N1 influenza virus as confirmed by RT-PCR. The remaining 6
samples corresponded to operative personnel from our H1N1
molecular diagnostic unit at Centro de Biotecnologı ´a-FEMSA. All
of these staff members participated directly in the manipulation of
naso-pharyngeal samples from potentially infected patients and/or
in the operations for extraction of viral RNA from these samples.
Figure 10 shows results of the specific antibody titers, expressed in
normalized absorbance units, found in these 28 samples.
Sixty percent of the samples from the medical personnel
exhibited specific antibody titers higher than 1.5 normalized
absorbance units (threshold observed to be reasonable to
conclusively discern between exposed and non-exposed subjects).
One hundred percent of samples corresponding to our molecular
diagnostic unit staff showed high titers of anti-2009 H1N1
influenza virus antibodies. Although this set of 28 volunteers is a
small and not necessarily representative sample, our results suggest
that a high percentage of health care personnel who presumably
come in contact with H1N1 patients could have a significant level
of protective antibodies against the infection.
Specificity
We have not conducted a formal study to evaluate possible
cross-reactivity of protein HA50–274-H1N1 with antibodies direct-
ed against other Influenza A strains. However, some observations
from the population of samples analyzed so far suggests that, as
Figure 8. Validation of sensitivity against an HI assay. Normalized absorbance values for fourteen samples with positive anti H1N1/2009 titters
based on an HI assay (samples that inhibited hemagglutination of turkey erythrocytes by the Ca/2009/H1N1 influenza virus strain at dilutions equal or
higher to 1:40). Colors indicate HI titter: HI titter=40 (in blue); HI titter=80 (in yellow); HI titter=160 (in orange); HI titter.320 (in red). The proposed
positive threshold for the ELISA method is indicated with a solid line (value=1). One standard deviation is indicated with a dashed line (value=1.25).
doi:10.1371/journal.pone.0010176.g008
H1N1/2009 ELISA
PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e10176expected, cross-reactivity is minimal. Of all the volunteers
identified by the assay as negative (26 individuals), 7 (27%)
declared themselves to have had an influenza-like disease during
the year 2008. Another 3 (11.5%) have been administered seasonal
vaccines during 2008. Therefore, we would presume that at least
38% of the negative subjects should have circulating influenza A
antibodies from seasonal strains.
Additional evidence of the specificity of the assay was provided
by the analysis of samples from four volunteers diagnosed as
positive and monitored throughout the first three weeks post-
infection. All of these volunteers vouched to having had influenza-
like illness recently (during the previous year). Two of these had
received the 2008 seasonal influenza vaccine. In all four of these
cases, their basal antibody titers were observed to be in the range
of those typical of negative subjects (normalized absorbance value
<1). In all cases, their antibody titers increased at least two fold by
the third week after infection. These results suggest that possibly
pre-existing antibodies against other influenza strains did not
significantly interfere with the assay.
In conclusion, the typical HI strategy for evaluating viral
infection suffers from a number of limitations that make this
strategy unworkable in the face of pandemic infection. The
requirement of vast quantities of fresh chicken or turkey
erythrocytes as one of the main materials required for the assays,
as well as the requirement for actual virus (and the corresponding
need for equipment and manpower for large-scale viral culture),
makes HI assays in typical laboratory settings impractical on a
population scale. In the present work, we present a virus-free
ELISA method that will allow the determination of relative
concentrations of antibodies specifically directed against the 2009
H1N1 influenza virus. The immunoassay is based on the use of a
recombinant fraction of hemagglutinin of the virus expressed in E.
coli. The proposed method conclusively discerns between exposed
and non-exposed subjects, particularly after the third week post-
infection. Although validated in the context of 2009 H1N1
influenza virus, the same method can conceptually be extended to
other seasonal and pandemic influenzas, simply by expression of
the corresponding specific recombinant protein HA50–274.
In comparison with typically used methods to titer viral
antibodies, this new method (a) does not require of the use of
actual viral particles; (b) does not depend on the use of poultry
erythrocytes; (c) it could be easily reproducible and implemented
in any typical laboratory setting by personnel with typical
laboratory skills.
Consequently, for massive epidemiological/clinical influenza
studies, the protocols presented here would expedite the
generation of reliable results that could be easily cloned in
multiple laboratories. However, an independent validation of the
ELISA specificity (i.e. a study in an independent test population
validating a normalized absorbance threshold for specific diagno-
sis) will be necessary before wider application of this ELISA as a
research tool can be recommended.
Materials and Methods
ELISA assay
We developed an ELISA method for the evaluation of presence
of specific 2009 H1N1 influenza virus-antibodies in serum samples
(Figure 3). Standard commercial 96-wells micro-assay plates
(CorningH, Maxisorp
TM; USA) were used. One hundred mLo fa
solution of 5 mg/mL of mouse anti-histidine tag antibodies (AbD
serotecH; UK) in PBS (pH 7.2+/20.2) were dispensed per well.
Plates were incubated for 12 to 16 h at room temperature to
conveniently fix the anti-histidine antibodies to the bottom surface
of each well. Excess antibody was removed by successive washing
steps with PBS-Tween 0.05% and PBS. At least two cycles of 5
minutes with PBS-Tween 0.05% followed by two cycles of 5
minutes with PBS in an automatic micro-plate washing instrument
are recommended. A volume of 300 mL of commercial blocking
solution (SuperblockH T20 PBS Blocking Buffer; Cat.No. 37516,
PierceH, USA) was added to each plate and incubated for at least
2 hours at room temperature to block the surface not covered with
antibodies. Excess blocking solution was removed by successive
washing steps with PBS-Tween 0.05%. A volume of 100 mLo fa
10 mg/mL solution of a non-glycosylated histidine tagged
recombinant protein was added to each well. The protein, the
main component of the assay, consisted of a fragment of the
hemagglutinin of the Influenza A/H1N1 virus (further details are
given below). The protein solution was incubated for at least 1 h at
room temperature to allow protein molecules to specifically bind
to the anti-histidine antibodies through their histidine tags. Wells
were washed repeatedly with PBS-Tween and PBS. At least two
cycles of 5 minutes with PBS-Tween 0.05% followed by two cycles
of 5 minutes with PBS in an automatic micro-plate washing
instrument are recommended to remove unattached protein. A
volume of 100 mL of the serum or plasma sample to be assayed
was added to each well to test for specific bio-recognition. Four
different serum dilution schemes in PBS were tested (1:200, 1:100,
1:50, and undiluted samples). Best results were obtained at 1:50
dilutions.
Figure 9. Reproducibility of the ELISA method for specific
evaluation of anti Influenza A/H1N1/2009 antibodies in serum
samples. Bars present the normalized absorbance value for samples of:
three independent replicates of the assay on a sample of a non-exposed
volunteer (bar 1); the average absorbance signal from eight different
non-exposed volunteers (bar 2); three independent replicates of assays
on samples taken two weeks after positive diagnostic on two different
Influenza A/H1N1/2009 infected volunteers (bars 3 and 4); three
independent replicates of assays on a sample taken three weeks after
positive diagnostic on a Influenza A/H1N1/2009 infected volunteer (bar
5); three independent replicates of assays on a sample taken four weeks
after positive diagnostic on a Influenza A/H1N1/2009 infected volunteer
(bar 6).
doi:10.1371/journal.pone.0010176.g009
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hour. After incubation, wells were washed repeatedly. At least two
cycles of 5 minutes with PBS-Tween 0.05% followed by two cycles
of 5 minutes with PBS in an automatic micro-plate washing
instrument are recommended. To reveal the amount of antibody
specifically bound in each well, a volume of 100 mL/well of an
anti-human IgG antibody solution (1:30000 dilution in PBS-
Tween 0.05%) marked with horse radish peroxidase (PierceH,
USA) was used. After incubating for one hour at room
temperature and washing repeatedly (at least two cycles of 5
minutes with PBS-Tween 0.05% followed by two cycles of 5
minutes with PBS in an automatic micro-plate washing instru-
ment), a 100 mL volume of substrate solution (1-Step Ultra TMB-
ELISA; Lot. 34028, PierceH) was added to each well. After
incubation for 1565 min at room temperature in darkness, the
enzymatic reaction was stopped by addition of 50 mL/well of a
1MH 2SO4. Color produced by the enzymatic reaction (from
colorless to yellow) was evaluated by absorbance at 450 nm in a
BiotekH microplate reader (USA).
Recombinant hemagglutinin
Specifically, the protein used for the ELISA method described
here was a fragment corresponding to a highly conserved region
among sequences of 2009 H1N1 influenza viruses reported at
NCBI. It was comprised of the amino acid sequence from residues
50 to 274 of the HA alignment consensus (referred as HA50–274-
H1N1):
GVAPLHLGKCNIAGWILGNPECESLSTASSWSYIVETSS-
SDNGTCYPGDFIDYEELREQLSSVSSFERFEIFPKTSSWPN-
HDSNKGVTAACPHAGAKSFYKNLIWLVKKGNSYPKLSK-
Figure 10. Normalized absorbance signals of serum samples from health care and diagnostic personnel in high exposure risk to the
Influenza A/H1N1/2009 virus. Bars 1–22 present signals corresponding to asymptomatic health care workers. Bars 24–29 present signals
corresponding to samples from H1N1 molecular diagnostic personnel. Bar 23 (negative reference) illustrates the average and standard deviation of
eight samples from non-exposed subjects.
doi:10.1371/journal.pone.0010176.g010
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GSSRYSKKFKPEIAIRPKVRDQEGRMNYYWTLVEPGDK-
ITFEATGNLVVPRYAFAMERNAGSGIIISD
The corresponding DNA sequence was obtained by back
translation of the open reading frame and was optimized for E.coli
expression (Figure 2). The gene was synthesized at DNA2.0 (San
Diego, CA, USA) and cloned into a pJexpress404 vector (San
Francisco, CA) in an E. coli Rosetta-gamiH strain (strain deposited
at ATCC by Alvarez et al. [44]). Given these genetic construction
and culture conditions (aerobic culture in an instrumented 5 L
bioreactor from New Brunswick Scientific, NJ, USA; 37uC,
agitation at 500 RPM, pH 7, and induction using IPTG),
practically all of the recombinant protein was expressed as
insoluble inclusion bodies. After cultivation, biomass was centri-
fuged at 30006g for 10 minutes. Twenty ml of TALONH
xTractor Buffer (Clontech Laboratories, Mountain View, CA)
were added per gram of wet cellular pellet to disrupt the cell
membrane and extract the inclusion bodies. A concentrated
solution of type I DNAases and Lysozyme 1X, was added to
further degrade cell membranes and degrade DNA, thereby
decreasing the viscosity of the solution and facilitating handling.
The resulting solution was centrifuged at 12,0006g for 30 minutes
at 4uC. A series of consecutive washing steps using PBS buffer
solution rendered a precipitate containing the protein of interest in
the insoluble fraction with a purity of above 90%. The protein was
dissolved using 8 M urea solution and the resulting solution was
passed through chromatography columns containing 2 mL of
TALONH Metal Affinity Resin (Clontech Laboratories, Mountain
View, CA) loaded with Co
+2 ions and equilibrated at pH 8 or
using a Ni
2+ charged resin (Profinia Protein Purification System
from Bio-Rad). While still attached to the resin through its
histidine tags, the HA50–274 protein was treated with successive
washes with PBS at pH 7 or 400 mM arginine at pH 8, to
promote refolding. The protein was eluted with 150 mM
imidazole at pH 7. Through this purification scheme, solutions
in the range of 400 to 650 mg/L with purities exceeding 99.5%
were obtained, as estimated by micro-elecrophoresis using an
ExperionH platform from Bio-rad (Hercules, CA). The robustness
of this general purification strategy was evaluated by examining
the performance of protein produced in five different refolding
batches derived from the same E. coli culture experiment.
Variation among batches consisted of minor deviations in the
dissolution and refolding protocol previously described: 1) for
batch 1, protein HA50–274-H1N1 was dissolved using a 8 M urea
solution and refolded on-column with a 400 mM arginine in PBS
using a Ni
2+ charged resin (Profinia Protein Purification System
from Bio-Rad); 2) for batch 2 a 8 M urea solution in PBS was used
as solubilization agent and refolding occurred by direct dilution
into 200 mM arginine using a dialysis system to exchange solvents;
3) for batch 3, an 8 M urea solution in PBS was used as
solubilization agent and refolding occurred by direct dilution in a
400 mM arginine using a dialysis system to exchange solvents; 4)
for batch 4 a 8 M urea solution in PBS was used as solubilization
agent and refolding was conducted on-column by continuous
passage of buffer solution PBS through a Ni
2+ charged resin
(Profinia Protein Purification System from Bio-Rad); and 5) batch
five was the reference batch, where protein HA50–274-H1N1 was
expressed in its soluble form using a signal peptide for periplasm
translocation (see [46]).
Serum samples
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
Institutional Review Board of the Escuela de Biotecnologı ´ay
Salud del Tecnolo ´gico de Monterrey. All volunteers provided
written informed consent for the collection of samples and
subsequent analysis.
Different experiments with human serum samples were
conducted. In a first experiment, aimed to validate the ability of
the ELISA protocol to discriminate subjects with high H1N1
specific antibody titers in general population, serum samples from
25 volunteers were collected and analyzed using the ELISA
protocols presented here. Samples were diluted 1:50 in PBS. These
25 samples corresponded to 3 different groups. Eight samples were
collected in Monterrey Nuevo Leo ´n,Me ´xico, from March to May
2008, practically one year before the onset of the pandemic.
Therefore, these subjects most probably corresponded to volun-
teers with no exposure to the Influenza A/H1N1/2009 virus. Five
samples were taken from healthy volunteers, selected on the basis
of a questionnaire designed to exclude any persons with symptoms
possibly associated with influenza like illness within a period of six
months previous to this study. In addition, 11 samples corre-
sponded to volunteers diagnosed as positive to Influenza A/
H1N1/2009 two to four weeks before the sample was taken
(presumably three to five weeks after infection). Positive volunteers
were recruited from regular patients from the Hospital San Jose ´
del Tecnolo ´gico de Monterrey admitted within the period of April
to October 2009. All diagnoses were confirmed using the specific
RT-PCR protocol developed by the Center for Prevention and
Disease Control (CDC) in Atlanta, Georgia, USA, and recom-
mended by the World Health Organization (WHO) [24] as the
reference method for the detection of the human Influenza A/
H1N1/2009 virus.
In a second experiment, 14 samples corresponding to subjects
with HI titters equal or higher than 40 (conventionally
considered as exposed to the virus based on the HI assay) were
tested by ELISA. A Influenza A/H1N1/CA/04/2009 virus
strain and Turkey erythrocytes were used for the HI experiments.
Dilutions in the range of 1:40 to 1:320 were considered. In a
third experiment, serum samples from 28 subjects assumed to be
at high exposure risk to the Influenza A/H1N1/2009 virus
(health care workers and diagnostics personnel) were studied. All
of these subjects declared not to have been clinically diagnosed or
symptomatic for influenza-like illness during at least during the
year 2009. These volunteers were diagnosed as negative to
Influenza A or Influenza A/H1N1 using the specific RT-PCR
protocol developed by CDC (Atlanta, USA) and recommended
by WHO for Human Influenza A/H1N1/2009 [27]. Volunteers
were selected from health workers who directly attended H1N1
positive patients at Hospital San Jose ´ (Monterrey, Me ´xico) and
personnel directly involved in the operation of the molecular
diagnostics lab at a Diagnostic Center in Monterrey located at
t h eC e n t r od eB i o t e c n o l o g ı ´a-FEMSA at Tecnolo ´gico de Mon-
terrey.
In addition, the evolution of specific titers against the Influenza
A/H1N1/2009 virus was followed in four volunteers diagnosed as
positive using RT-PCR protocols. Subjects were required to
donate blood samples during three weeks from the day they were
diagnosed. Samples from one of these volunteers corresponding to
21, 100, and 250 days after the onset of disease were collected and
analyzed to determine long term evolution of specific antibody
titters.
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